Subversive Subjects: Rule-Breaking and Deception in Clinical Trials

Journal of Law, Medicine and Ethics

Volumn 41, Issue 4, 2013, Pages 829-840

  Dresser, Rebecca ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL (TOPIC); DECEPTION; HUMAN; MEDICATION COMPLIANCE; RESEARCH ETHICS; RESEARCH SUBJECT;

CLINICAL TRIALS AS TOPIC; DECEPTION; ETHICS, RESEARCH; HUMANS; MEDICATION ADHERENCE; RESEARCH SUBJECTS;

EID: 84892886983     PISSN: 10731105     EISSN: 1748720X     Source Type: Journal    
DOI: 10.1111/jlme.12093     Document Type: Article

References (77)

1. S. Epstein, Impure Science: AIDS, Activism, and the Politics of Knowledge (Berkeley: University of California Press, 1996): at 204
2. Researcher Kenneth Shulz observed that because requirements like randomization "annoy human nature," people involved in research may be tempted to evade those requirements
3. K. F. Schulz, "Subverting Randomization in Controlled Trials," Journal of the American Medical Association 274, no. 18 (1995): 1456-1458
4. D. L. Smith, "Patient Nonadherence in Clinical Trials: Could There Be a Link to Postmarketing Patient Safety?" Drug Information Journal 46, no. 1 (2012): 27-34
5. S. A. Shumaker, E. Dugan, and D. J. Bowen, "Enhancing Adherence in Randomized Controlled Clinical Trials," Controlled Clinical Trials 21, no. 5 (2000): 226S-232S
6. Some rule violations have a more serious impact on research findings than do other violations. But any violation of a rule designed to strengthen the validity of data presents a threat to study quality.
7. D. Wendler and F. G. Miller, "Deception in Clinical Research," in E. J. Emanuel et al., eds., Oxford Textbook of Clinical Research Ethics (Oxford: Oxford University Press, 2008): at 315-324
8. Articles from the publication are collected in R. Helms, ed., Guinea Pig Zero: An Anthology of the Journal for Human Research Subjects (New Orleans: Garrett County Press, 2002
9. The publication is availablehttp://www.guineapigzero. com2013
10. R. Abadie, The Professional Guinea Pig: Big Pharma and the Risky World of Human Subjects (Durham, North Carolina: Duke University Press, 2010
11. D. B. Resnik and G. Koski, "A National Registry for Healthy Volunteers in Phase 1 Clinical Trials," Journal of the American Medical Association 305, no. 12 (2011): 1236-1237
12. C. L. Tishler and S. Bartholomae, "Repeat Participation Among Normal Healthy Research Volunteers," Perspectives in Biology and Medicine 46, no. 4 (2003): 508-520
13. G. Apseloff, J. K. Swayne, and N. Gerber, "Medical Histories May Be Unreliable in Screening Volunteers for Clinical Trials," Clinical Pharmacology & Therapeutics 60, no. 3 (1996): 353-356
14. R. Hermann, D. Heger-Mahn, M. Mahler, M. Seibert-Grafe, C. Klipping, K. Breithaupt-Grogler, and C. de Mey, "Adverse Events and Discomfort in Studies on Healthy Subjects: The Volunteer's Perspective," European Journal of Clinical Pharmacology 53, nos. 3-4 (1997): 207-214
15. J. McHugh, "Drug Test Cowboys: The Secret World of Pharmaceutical Trial Subjects," Wired, April 24, 2007http://www.wired. com/wired/archive/15.05/feat_drugtest.html
16. M. Patriquin, "Inside the Human Guinea Pig Capital of North America," MacLeans 122, no. 33 (2009)
17. A University of Pennsylvania School of Medicine official observed, "We ask subjects to disclose if they're participating in other trials-but if someone wants to lie, I won't necessarily know if they're simultaneously doing a trial across town
18. D. Glenn, "Inside the Risky World of Drug- Trial 'Guinea Pigs,'" Chronicle of Higher Education, July 11, 2010
19. C. Elliott, "Guinea-Pigging," The New Yorker, January 7, 2008
20. L. P. Cohen, "Stuck for Money: To Screen New Drugs for Safety, Lilly Pays Homeless Alcoholics," Wall Street Journal, November 14, 1996
21. These terms are used interchangeably. Both terms are criticized on grounds that they "subtly exaggerate the importance of the clinician," suggesting a hierarchical rather than egalitarian relation between the medical professional and layperson
22. J. F. Steiner and M. A. Earnest, "The Language of Medication- Taking," Annals of Internal Medicine 132, no. 11 (2000): 926- 30
23. S. Holm, "What Is Wrong With Compliance?" Journal of Medical Ethics 19, no. 2 (1993): 108-110
24. J. A. Fisher, Medical Research for Hire: The Political Economy of Pharmaceutical Clinical Trials (New Brunswick, NJ: Rutgers University Press, 2009): at 187
25. R. Abadie, "Tracking Professional Guinea Pigs," October 15, 2010http://www.thehastingscenter.org/Bioethicsforum/Post. aspx?id=4933&blogid=140
26. For a description of payment practices in studies offering payment to both healthy volunteers and patient-subjects
27. C. Grady, N. Dickert, T. Jawetz, G. Gensler, and E. Emanuel, "An Analysis of U.S. Practices of Paying Research Participants," Contemporary Clinical Trials 26, no. 3 (2005): 365-375
28. M. S. Simmons, M. A. Nides, C. S. Rand, R. A. Wise, and D. P. Tashkin, "Unpredictability of Deception in Compliance with Physician-Prescribed Bronchodilator Use in a Clinical Trial," Chest 118, no. 2 (2000): 290-295
29. J. Cohen, "Human Nature Sinks HIV Prevention Trial," http://news.sciencemag.org/sciencenow/2013/03/ human-nature-sinks-hiv-preventio.html
30. C. Bradley, "Designing Medical and Educational Intervention Studies," Diabetes Care 16, no. 2 (1993): 509-18
31. C. Brewin and C. Bradley, "Patient Preferences and Randomised Clinical Trials," BMJ 299, no. 6694 (1989): 313-315
32. A. Moyer, "Psychomethodology: The Psychology of Human Participation in Science," Journal of Psychology of Science and Technology 2, no. 2 (2009): 59-72
33. R. Finn, Cancer Clinical Trials: Experimental Treatments & How They Can Help You (Sebastopol, CA: O'Reilly, 1999): at 18-31
34. C.F.R. 46.116(a) (8) (2011
35. At the same time, individuals ought to enter trials with a good faith intention to remain unless participation becomes too burdensome.
36. H. Mann, "Deception in the Single-Blind Run-In Phase of Clinical Trials," IRB: Ethics & Human Research 29, no. 2 (2007): 14-17
37. F. Miller, D. Wendler, and L. Swartzman, "Deception Research on the Placebo Effect," PLoS Medicine 2, no. 9 (2005): 853-859
38. G. C. Blackhart, K. E. Brown, T. Clark, D. L. Pierce, and K. Shell, "Assessing the Adequacy of Postexperimental Inquiries in Deception Research and the Factors that Promote Participant Honesty," Behavior Research Methods 44, no. 1 (2012): 24-40
39. D. B. Resnik and E. Ness, "Participants' Responsibilities in Clinical Research," Journal of Medical Ethics 38, no. 12 (2012): 746-750
40. M. Mitka, "FDA and Pharma Seek Better Ways to Assess Drug Safety, Efficacy in Clinical Trials," JAMA 307, no. 24 (2012): 2576-2577
41. S. Rice and D. Trafimow, "Known versus Unknown Threats to Internal Validity," American Journal of Bioethics 11, no. 4 (2011): 20-21
42. A. Shamoo and D. B. Resnik, "Strategies to Minimize Risks and Exploitation in Phase One Trials on Healthy Subjects," American Journal of Bioethics 6, no. 3 (2006): W1-W13
43. F. G. Miller and A. Wertheimer, "Facing Up to Paternalism in Research Ethics," Hastings Center Report 37, no. 3 (2007): 24-34
44. K. De Ville, "The Case Against Contract: Participant and Investigator Duty in Clinical Trials," American Journal of Bioethics 11, no. 4 (2011): 16-18
45. "Just Another Lab Rat! Mission Statementjalr.org/mission.html
46. The website is a project of Paul Clough, a man who earns his living through clinical trial participation
47. A. O'Meara, Chasing Medical Miracles: The Promise and Perils of Clinical Trials (New York: Walker & Company, 2009): at 111-112
48. G. O. Schaefer, E. J. Emanuel, and A. Wertheimer, "The Obligation to Participate in Research," Journal of the American Medical Association 302, no. 1 (2009): 67-72
49. Elliott, "Research Volunteers Wanted. Earn Up to $7000," Tin House, Spring 2008, at 103-06
50. Public Responsibility in Medicine and Research, "In Their Own Voices: A Discussion with Research Subjects Who Also Work in The Field of Subject Protection 2010http://www. meetingproceedings.com/2010/aerc/contents/index.asp
51. Guinea Pigs Get Paid, "Tips for Clinical Trials and Clinical Study Volunteers," 2009http://www.gpgp.net/ tips.html
52. Public Responsibility in Medicine and Research, "What Do Research Subjects Have to Say about Informed Consent?" December 3, 2011http://www.eventscribe. com/2011/PRIMR/SearchByDay.asp?day=12/3/2011
53. Public Responsibility in Medicine and Research, "A Discussion with Research Subjects and Their Advocates," November 15, 2009http://www.meetingproceedings. com/2009/aerc/contents/index.asp
54. D. L. Shelton, "Patients in Clinical Trials Don't Always Follow the Program," American Medical News, September 11, 2000
55. C. S. Rand and M. A. Sevick, "Ethics in Adherence Promotion and Monitoring," Controlled Clinical Trials 21, no. 5 (2000): 241S-247S
56. S. Redfearn, "Smart-Pill Technology Could Monitor Patient Compliance While Improving Clinical Trial Data Quality," 2011http://www.centerwatch.com/ news-online/article/1338/
57. For this reason, a private U.S. venture called Verified Clinical Trials is attempting to establish a worldwide registry. "Verified Clinical Trials," http://www.verifiedclinicaltrials.com
58. S. Edwards, "Assessing the Remedy: The Case for Contracts in Clinical Trials," American Journal of Bioethics 11, no. 4 (2011): 3-12
59. J. Robertson, "Contractual Duties in Research, Surrogacy, and Stem Cell Donation," American Journal of Bioethics 11, no. 4 (2011): 13-14
60. N. K. Reame, "Treating Research Subjects as Unskilled Wage Earners: A Risky Business," American Journal of Bioethics 1, no. 2 (2001): 53-54
61. C. Elliott, "Justice for Injured Research Subjects," New England Journal of Medicine 367, no. 1 (2012): 6-8
62. R. Dresser, "Aligning Regulations and Ethics in Human Research," Science 337, no. 6094 (2012): 527-528
63. Abadie reports that in recent years, competition among research organizations has produced improved conditions in some locales but not others
64. He also learned that some guinea pigs do not like the "fancy sites" because they are too large and impersonal
65. The comments on staff behavior bring to mind Michael Kahn's plea for more emphasis on basic etiquette in medical training: "The very notion of good manners may seem quaint or anachronistic, but it is at the heart of the mission of other service-related professions. The goals of a doctor differ in obviously important ways from those of a Nordstrom's employee, but why shouldn't the clinical encounter similarly emphasize the provision of customer satisfaction through explicit actions?
66. M. Kahn, "Etiquette-Based Medicine," New England Journal of Medicine 358, no. 19 (2008): 1988-89
67. D. McDonald and M. J. Lamberti, "The Psychology of Clinical Trials: Understanding Physician Motivation and Patient Perception," Centerwatch Research Brief, October 4, 2006http://www.centerwatch.com/news-online/article/566/the-psychology-of-clinical-trials-understanding-physician-motivation-and-patient-perception
68. R. Dresser, When Science Offers Salvation: Patient Advocacy and Research Ethics (New York: Oxford University Press, 2001): at 21-43
69. N. Weisfeld, R. A. English, and A. B. Claiborne, Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020 (Washington, DC: National Academies Press, 2012
70. W. Meurer, R. Lewis, and D. Berry, "Adaptive Clinical Trials: A Partial Remedy for the Therapeutic Misconception?" Journal of the American Medical Association 307, no. 22 (2012): 2377-78
71. A. Floyd and A. Moyer, "Effects of Participant Preferences in Unblinded Randomized Controlled Trials," Journal of Empirical Research on Human Research Ethics 5, no. 2 (2010): 81-93
72. M. Janevic, N. K. Janz, J. A. Dodge, X. Lin, W. Pan, B. R. Sinco, and N. M. Clark, "The Role of Choice in Health Education Intervention Trials: A Review and Case Study," Social Science and Medicine 56, no. 7 (2003): 1581-1594
73. J. A. Lynch, "'Through a Glass Darkly': Researcher Ethnocentrism and the Demonization of Research Participants," American Journal of Bioethics 11, no. 4 (2011): 22-23
74. V. Marsh, D. Kamuya, Y. Rowa, C. Gikonyo, and S. Molyneux, "Beginning Community Engagement at a Busy Biomedical Research Programme: Experiences from the KEMRI CGMRC-Wellcome Trust Research Programme," Social Science & Medicine 67, no. 5 (2008): 721-733
75. H. Jonas, "Philosophical Reflections on Experimenting with Human Subjects," Daedalus, 98, no. 2 (1969): 219-247
76. Empirical evidence should be collected on the effectiveness of different strategies to reduce rule-breaking.
77. L. Stunkel and C. Grady, "More Than the Money: A Review of the Literature Examining Healthy Volunteer Motivations," Contemporary Clinical Trials 32, no. 3 (2011): 342-352